Andrea Vergara

Ms. Andrea Vergara

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2018 in JAMA
Verified
Journal Article
Open access
PDF file
BWBastiaan H. Wittekamp
Bastiaan H. Wittekamp
NPNienke L. Plantinga
Nienke L. Plantinga
BCBen S. Cooper
Ben S. Cooper
JLJoaquin Lopez-Contreras
Joaquin Lopez-Contreras
PCPere Coll
Pere Coll
MBMarc J. M. Bonten
Marc J. M. Bonten
Care of patients in intensive care units (ICUs) is frequently complicated by infections, which are associated with increased morbidity, mortality, and health care costs.1,2 Selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) consist of topical antimicrobial agents targeting aerobic gram-negative pathogens, Staphylococcus aureus, and yeasts in the gastrointestinal tract (SDD) and oropharynx (SDD/SOD), and they aim to prevent infections. In ICUs with low levels of antibiotic resistance, SDD and SOD have been associated with improved patient outcomes,3,4 with SDD being more efficacious than SOD.5,6 Currently, SDD and SOD are routinely used in ICUs in the Netherlands, but their use has not been widely adopted in other countries,7 mainly because of limited efficacy data in settings with higher levels of antibiotic resistance and concern about emergence of antibiotic resistance, although the latter is not supported by meta-analyses.8 In contrast, chlorhexidine (CHX) mouthwash is widely used in ICU patients and its use has been associated with a lower incidence of ventilator-associated pneumonia,9,10 with CHX 2% being more efficacious than lower concentrations.9 Yet, in meta-analyses, CHX mouthwash was associated with higher mortality in ICU patients.11,12 SDD and SOD have never been compared head to head with CHX mouthwash in ICU patients.

15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
ASAna Esteve Solé
Ana Esteve Solé
JAJordi Anton
Jordi Anton
RPRosa Maria Pino-Ramirez
Rosa Maria Pino-Ramirez
JSJudith Sanchez-Manubens
Judith Sanchez-Manubens
Victoria FumadóVictoria Fumadó
Victoria Fumadó
LALaia Alsina
Laia Alsina
Multisystem inflammatory syndrome associated with the SARS-CoV-2 pandemic has recently been described in children (MIS-C), partially overlapping with Kawasaki disease (KD). We hypothesized that (a) MIS-C and prepandemic KD cytokine profiles may be unique and justify the clinical differences observed, and (b) SARS-CoV-2–specific immune complexes (ICs) may explain the immunopathology of MIS-C. Seventy-four children were included: 14 with MIS-C, 9 patients positive for SARS-CoV-2 by PCR without MIS-C (COVID), 14 with prepandemic KD, and 37 healthy controls (HCs). Thirty-four circulating cytokines were quantified in pretreatment serum or plasma samples and the presence of circulating SARS-CoV-2 ICs was evaluated in MIS-C patients. Compared with HCs, the MIS-C and KD groups showed most cytokines to be significantly elevated, with IFN-γ–induced response markers (including IFN-γ, IL-18, and IP-10) and inflammatory monocyte activation markers (including MCP-1, IL-1α, and IL-1RA) being the main triggers of inflammation. In linear discriminant analysis, MIS-C and KD profiles overlapped; however, a subgroup of MIS-C patients (MIS-Cplus) differentiated from the remaining MIS-C patients in IFN-γ, IL-18, GM-CSF, RANTES, IP-10, IL-1α, and SDF-1 and incipient signs of macrophage activation syndrome. Circulating SARS-CoV-2 ICs were not detected in MIS-C patients. Our findings suggest a major role for IFN-γ in the pathogenesis of MIS-C, which may be relevant for therapeutic management.

1 August 2018 in Human Microbiome Journal
Verified
Journal Article
Open access
CCCliment Casals-Pascual
Climent Casals-Pascual
AVAndrea Vergara
Andrea Vergara
Jordi VilaJordi Vila
Jordi Vila

26 November 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SGSergio García-Fernández
Sergio García-Fernández
MMMaría-Isabel Morosini
María-Isabel Morosini
FMFrancesc David Marco
Francesc David Marco
DGDesirèe Gijón
Desirèe Gijón
AVAndrea Vergara
Andrea Vergara
RCRafael Cantón
Rafael Cantón
To evaluate the performance of the eazyplex® SuperBug CRE system, a loop-mediated isothermal amplification (LAMP)-based system, for confirming the presence of carbapenemases in addition to CTX-M-type ESBLs in previously genotypically and/or phenotypically characterized clinical Enterobacteriaceae isolates recovered in two centres in Spain. A collection of 94 carbapenemase-producing strains previously characterized by conventional PCR and sequencing and a total of 45 prospectively collected isolates with phenotypes compatible with the presence of a carbapenemase were tested with the eazyplex® SuperBug CRE system. In both cases, the presence of an ESBL was also assessed. Results were evaluated to establish the accuracy of this rapid LAMP-based system as well as to determine the concordance between all approaches. The eazyplex® SuperBug CRE system correctly detected bla carbapenemase genes with or without blaCTX-M genes in 100% of the molecularly characterized strains. Absolute concordance (100%) was also observed in the case of isolates with phenotypes compatible with the presence of a carbapenemase with or without an ESBL inferred by susceptibility patterns and phenotypic inhibitory profiles. Determinations performed with the eazyplex® SuperBug CRE system took 15 min. The eazyplex® SuperBug CRE system proved to be a powerful tool for the detection of different carbapenemases as well as CTX-M-type ESBLs in Enterobacteriaceae with a rapid resolution time. The test has the high-performance parameters attributable to the sensitivity and specificity already demonstrated by LAMP-based assays. These results assure the usefulness of this test for routine rapid confirmation of carbapenemase-producing Enterobacteriaceae.

1 June 2016 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
YZY. Zboromyrska
Y. Zboromyrska
ERE. Rubio
E. Rubio
IAI. Alejo
I. Alejo
AVAndrea Vergara
Andrea Vergara
AMA. Mons
A. Mons
Jordi VilaJordi Vila
Jordi Vila

12 March 2019 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
YZYuliya Zboromyrska
Yuliya Zboromyrska
Catia CillonizCatia Cilloniz
Catia Cilloniz
NCNazaret Cobos-Trigueros
Nazaret Cobos-Trigueros
MAManel Almela
Manel Almela
JNJuan Carlos Hurtado Negreiros
Juan Carlos Hurtado Negreiros
JVJordi Vila
Jordi Vila
Sepsis is a serious health condition worldwide, affecting more than 30 million people globally each year. Blood culture (BC) is generally used to diagnose sepsis because of the low quantity of microbes occurring in the blood during such infections. However, ~50% of bloodstream infections (BSI) give negative BC, this figure being higher for sepsis, which delays the start of appropriate antimicrobial therapy. This prospective study evaluated a multiplex real-time polymerase chain reaction, the MagicplexTM Sepsis test (MP), for the detection of pathogens from whole blood, comparing it to routine BC. We analyzed 809 blood samples from 636 adult patients, with 132/809 (16.3%) of the samples positive for one or more relevant microorganism according to BC and/or MP. The sensitivity and specificity of MP were 29 and 95%, respectively, while the level of agreement between BC and MP was 87%. The rate of contaminated samples was higher for BC (10%) than MP (4.8%) (P < 0.001). Patients with only MP-positive samples were more likely to be on antimicrobial treatment (47%) than those with only BC-positive samples (18%) (P = 0.002). In summary, the MP test could be useful in some clinical setting, such as among patients on antibiotic therapy. Nevertheless, a low sensitivity demonstrated impairs its use as a part of a routine diagnostic algorithm.